Literature DB >> 23072835

Effects of chronic buspirone treatment on cocaine self-administration.

Nancy K Mello1, Peter A Fivel, Stephen J Kohut, Jack Bergman.   

Abstract

Cocaine abuse and dependence is a major public health problem that continues to challenge medication-based treatment. Buspirone (Buspar) is a clinically available, non-benzodiazepine anxiolytic medication that acts on both serotonin and dopamine systems. In recent preclinical studies, acute buspirone treatment reduced cocaine self-administration at doses that did not also decrease food-reinforced behavior in rhesus monkeys (Bergman et al, 2012). The present study evaluated the effectiveness of chronic buspirone treatment on self-administration of cocaine and food. Five adult rhesus monkeys (Macaca mulatta) were trained to self-administer cocaine and food during four 1-h daily sessions under a second-order schedule of reinforcement (FR2 [VR 16:S]). Buspirone (0.32 and 0.56 mg/kg/h) was administered intravenously through one lumen of a double-lumen catheter every 20 min for 23 h each day for 7-10 consecutive days. Each buspirone treatment period was followed by saline control treatment until drug- and food-maintained responding returned to baseline levels. Buspirone significantly reduced responding maintained by cocaine, and shifted the dose-effect curve downwards. Buspirone had minimal effects on food-maintained responding. In cocaine discrimination studies, buspirone (0.1-0.32 mg/kg, IM) did not antagonize the discriminative stimulus and rate-altering effects of cocaine in four of six monkeys. These findings indicate that buspirone selectively attenuates the reinforcing effects of cocaine in a nonhuman primate model of cocaine self-administration, and has variable effects on cocaine discrimination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072835      PMCID: PMC3547196          DOI: 10.1038/npp.2012.202

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  71 in total

1.  The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.

Authors:  P M Beardsley; P Sokoloff; R L Balster; J C Schwartz
Journal:  Behav Pharmacol       Date:  2001-02       Impact factor: 2.293

Review 2.  Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view.

Authors:  Roberto Mandrioli; Laura Mercolini; Maria Augusta Raggi
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

3.  Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala.

Authors:  Patricia Di Ciano
Journal:  Behav Neurosci       Date:  2008-02       Impact factor: 1.912

4.  The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2005-10-05       Impact factor: 7.853

5.  Discriminative stimulus effects of dopaminergic agents in rhesus monkeys.

Authors:  L Koetzner; A L Riley; J R Glowa
Journal:  Pharmacol Biochem Behav       Date:  1996-06       Impact factor: 3.533

6.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

7.  Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists.

Authors:  P M Callahan; K A Cunningham
Journal:  Neuropharmacology       Date:  1997-03       Impact factor: 5.250

8.  Pharmacokinetics of buspirone following oral administration to rhesus monkeys.

Authors:  P H Marathe; F Shen; P Markham; D S Greene
Journal:  J Pharm Pharmacol       Date:  1999-05       Impact factor: 3.765

9.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

10.  A primate model of polydrug abuse: cocaine and heroin combinations.

Authors:  N K Mello; S S Negus; S E Lukas; J H Mendelson; J W Sholar; J Drieze
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  23 in total

1.  Differential effects of acute and chronic treatment with the α2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys.

Authors:  Stephen J Kohut; Peter A Fivel; Nancy K Mello
Journal:  Drug Alcohol Depend       Date:  2013-08-11       Impact factor: 4.492

Review 2.  Unpredictability as a modulator of drug self-administration: Relevance for substance-use disorders.

Authors:  Sally L Huskinson
Journal:  Behav Processes       Date:  2020-06-08       Impact factor: 1.777

3.  Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys.

Authors:  Gregory T Collins; Charles P France
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-28       Impact factor: 3.157

Review 4.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

5.  The effects of buspirone on occupancy of dopamine receptors and the rat gambling task.

Authors:  Patricia Di Ciano; Patrick Mc Cormick; Cristiana Stefan; Ernest Wong; Aaron Kim; Gary Remington; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-08-19       Impact factor: 4.530

6.  Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Authors:  Morgane Thomsen; Andrew C Barrett; Paul Butler; S Stevens Negus; S Barak Caine
Journal:  J Pharmacol Exp Ther       Date:  2017-05-04       Impact factor: 4.030

Review 7.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

8.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

9.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.

Authors:  Yongkai Cao; Ningning Sun; Jiumei Zhang; Zhiguo Liu; Yi-Zhe Tang; Zhengzhi Wu; Kyeong-Man Kim; Seung Hoon Cheon
Journal:  Medchemcomm       Date:  2018-06-14       Impact factor: 3.597

10.  Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut
Journal:  Neuropsychopharmacology       Date:  2013-01-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.